- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Xencor is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.73 – a decrease of 4.16% over the previous week. Xencor employs 280 staff and has a trailing 12-month revenue of around $85.2 million.
Our top picks for where to buy Xencor stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Xencor stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – XNCR. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Xencor stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Xencor stock price (NASDAQ: XNCR)
Use our graph to track the performance of XNCR stocks over time.Xencor shares at a glance
Information last updated 2024-12-18.
| Latest market close | $23.73 |
|---|---|
| 52-week range | $15.31 - $27.24 |
| 50-day moving average | $23.12 |
| 200-day moving average | $21.09 |
| Wall St. target price | $32.91 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.18 |
Is it a good time to buy Xencor stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Xencor price performance over time
Historical closes compared with the close of $23.73 from 2024-12-18
| 1 week (2024-12-12) | -4.16% |
|---|---|
| 1 month (2024-11-20) | 0.04% |
| 3 months (2024-09-19) | 11.93% |
| 6 months (2024-06-18) | 22.07% |
| 1 year (2023-12-19) | 11.99% |
|---|---|
| 2 years (2022-12-19) | -8.52% |
| 3 years (2021-12-17) | 38.04 |
| 5 years (2019-12-19) | 38.68 |
Xencor financials
| Revenue TTM | $85.2 million |
|---|---|
| Gross profit TTM | $-34,984,000 |
| Return on assets TTM | -15.24% |
| Return on equity TTM | -29.02% |
| Profit margin | -232.77% |
| Book value | $10.35 |
| Market Capitalization | $1.7 billion |
TTM: trailing 12 months
Xencor share dividends
We're not expecting Xencor to pay a dividend over the next 12 months.
Xencor share price volatility
Over the last 12 months, Xencor's shares have ranged in value from as little as $15.31 up to $27.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.656. This would suggest that Xencor's shares are less volatile than average (for this exchange).
Xencor overview
Xencor, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression.
Frequently asked questions
What percentage of Xencor is owned by insiders or institutions?Currently 0.892% of Xencor shares are held by insiders and 104.549% by institutions. How many people work for Xencor?
Latest data suggests 280 work at Xencor. When does the fiscal year end for Xencor?
Xencor's fiscal year ends in December. Where is Xencor based?
Xencor's address is: 465 North Halstead Street, Pasadena, CA, United States, 91107 What is Xencor's ISIN number?
Xencor's international securities identification number is: US98401F1057 What is Xencor's CUSIP number?
Xencor's Committee on Uniform Securities Identification Procedures number is: 98401F105
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question